These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9789505)

  • 21. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.
    Hirsch MS; Steigbigel RT; Staszewski S; McMahon D; Fischl MA; Hirschel B; Squires K; DiNubile MJ; Harvey CM; Chen J; Leavitt RY;
    Clin Infect Dis; 2003 Oct; 37(8):1119-24. PubMed ID: 14523778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Data in from first head-to-head protease inhibitor.
    AIDS Patient Care STDS; 1998 Apr; 12(4):317. PubMed ID: 11361961
    [No Abstract]   [Full Text] [Related]  

  • 23. Effortless unintentional smoking cessation after lamivudine-zidovudine-indinavir post-exposure anti-HIV chemoprophylaxis.
    Simini B; Lucchesi C
    Addiction; 1999 Jan; 94(1):139-40. PubMed ID: 10665106
    [No Abstract]   [Full Text] [Related]  

  • 24. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.
    Rinaldo CR; Liebmann JM; Huang XL; Fan Z; Al-Shboul Q; McMahon DK; Day RD; Riddler SA; Mellors JW
    J Infect Dis; 1999 Feb; 179(2):329-36. PubMed ID: 9878015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.
    Nerad JL; Kessler HA
    Clin Infect Dis; 2001 Jun; 32(11):1635-6. PubMed ID: 11340537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis.
    Katzenstein TL; Dickmeiss E; Aladdin H; Hede A; Nielsen C; Nielsen H; Jørgensen LB; Gerstoft J
    Ann Intern Med; 2000 Jul; 133(1):31-4. PubMed ID: 10877737
    [No Abstract]   [Full Text] [Related]  

  • 27. [AZT and 3TC treatment in a pregnant woman with HIV infection].
    Pardo MJ; Pedrol E; Coll M; Montull S
    Med Clin (Barc); 1999 Mar; 112(9):358-9. PubMed ID: 10220772
    [No Abstract]   [Full Text] [Related]  

  • 28. Triple-drug therapy may mean lifelong commitment.
    AIDS Alert; 1999 Jan; 14(1):3-5. PubMed ID: 11366090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
    Rabaud C; Bevilacqua S; Beguinot I; Dorvaux V; Schuhmacher H; May T; Canton P
    Clin Infect Dis; 2001 May; 32(10):1494-5. PubMed ID: 11317252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Frothingham R
    Arch Intern Med; 1998 Jul; 158(13):1470-2. PubMed ID: 9665362
    [No Abstract]   [Full Text] [Related]  

  • 31. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.
    Rabaud C; Burty C; Grandidier M; Christian B; Penalba C; Béguinot I; Jeanmaire H; May T
    Clin Infect Dis; 2005 Jan; 40(2):303-5. PubMed ID: 15655751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elective cesarean delivery plus short-course lamivudine and zidovudine for the prevention of mother-to-child transmission of human immunodeficiency virus type 1.
    Panburana P; Sirinavin S; Phuapradit W; Vibhagool A; Chantratita W
    Am J Obstet Gynecol; 2004 Mar; 190(3):803-8. PubMed ID: 15042018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AIDS in the Third World: how to stop the HIV infection?
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):65-80. PubMed ID: 17550059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
    Kahn JO; Martin JN; Roland ME; Bamberger JD; Chesney M; Chambers D; Franses K; Coates TJ; Katz MH
    J Infect Dis; 2001 Mar; 183(5):707-14. PubMed ID: 11181146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].
    Eiros Bouza JM; Ortega Lafont M; Ortiz de Lejarazu R; Bachiller Luque P; de Luis Román DA
    An Med Interna; 2003 May; 20(5):239-42. PubMed ID: 12831297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rapid development of anemia in a HIV-positive patient with alpha-thalassemia after zidovudine therapy].
    Altinbaş A; Ozkaya G; Büyükaşik Y; Unal S
    Mikrobiyol Bul; 2007 Jul; 41(3):473-6. PubMed ID: 17933262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postexposure treatment of HIV.
    Pinkerton SD; Holtgrave DR; Bloom FR
    N Engl J Med; 1997 Aug; 337(7):500-1. PubMed ID: 9254338
    [No Abstract]   [Full Text] [Related]  

  • 38. Report updates recommendations for health workers exposed to HIV.
    Am J Health Syst Pharm; 1998 Sep; 55(17):1755. PubMed ID: 9867409
    [No Abstract]   [Full Text] [Related]  

  • 39. Medical student electives and infectious diseases. Zidovudine alone is not recommended prophylaxis.
    Meadway J
    BMJ; 1999 Apr; 318(7191):1145-6. PubMed ID: 10213754
    [No Abstract]   [Full Text] [Related]  

  • 40. Postsexual exposure prophylaxis.
    Klaus BD; Grodesky MJ
    Nurse Pract; 1998 Aug; 23(8):70, 72-3. PubMed ID: 9718603
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.